Article Figures & Data
Figures
- Figure 1.
Benefit of Cardiac Resynchronization Therapy in the COMPANION Trial
CRT=cardiac resynchronization therapy; CRT-D=cardiac resynchronization therapy plus implantable defibrillator; OPT=optimized medical therapy.
Reproduced from Lindenfeld J et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survial and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115:204–212. With permission from Lippincott, Williams and Wilkins.
- Figure 2.
Effect of NT-proBNP-Guided Therapy on Event-Free Survival in Heart Failure
NT-proBNP=N-terminal prohormone of brain natriuretic peptide.
Reproduced from Januzzi JL Jr et al. Use of amino-terminal pro-B-natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58(18):1881–1889. With permission from Elsevier.
- Figure 3.
Effect of Serelaxin Treatment on All-Cause Death in Patients With Heart Failure
Reproduced from Teerlink JR et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381(9860):29–39. With permission from Elsevier.
- Figure 4.
Effect of Cell. Therapy on Infarct Scar Size
CDC=cardiosphere-derived cells; EED=early enhancement defect; MI=myocardial infarction; MSCs=mesenchymal stem cells.
Reproduced from Telekuntla KS et al. The Advancing Field of Cell-Based Therapy: Insights and Lessons From Clinical Trials. J Am Heart Assoc 2013. With permission from Lippincott, Williams and Wilkins.
Tools
Table of contents
Cited By...
- No citing articles found.